Royal Bank of Canada
EIKN

Royal Bank of Canada’s Eikon Therapeutics EIKN Stock Holding History

Royal Bank of Canada’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36K Buy
+2,784
New +$28.4K ﹤0.01% 5980

Other funds holding EIKN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Royal Bank of Canada's EIKN Position: Q2 2026 in Review

Royal Bank of Canada opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 2,784 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #5980 among its holdings.

77 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Royal Bank of Canada held 2,784 shares of Eikon Therapeutics worth $36K as of Q2 2026.
  • Eikon Therapeutics was a new Royal Bank of Canada position in Q2 2026.
  • Eikon Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #5980 holding.
  • 77 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.